Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 1.01
INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-01
Item 7.01
The filing discloses positive Phase III results from an AI-driven drug discovery program with Yuva Biosciences, in which four small-molecule candidates demonstrated statistically significant ANT1 induction in human skeletal muscle cells. This represents a material operational and strategic milestone in the Company's drug development pipeline, supporting advancement to confirmatory testing. While not a traditional earnings release, M&A activity, or governance event, the disclosure of significant preclinical validation results for a lead development program is material to investors' assessment of the Company's pipeline progress and strategic direction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 3.02
SunPower closed a $10 million share exchange on July 1, 2026, whereby convertible note holders exchanged cash interest payments due on the notes for 19.3 million shares of common stock issued under Section 4(a)(2) exemption. This unregistered equity issuance materially restructures the company's capital obligations by converting future cash interest payments into equity, significantly diluting existing shareholders.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-01
EX-99.1
Park Ha Biological announced a formal membership application to the Personal Care Products Council (PCPC), described as "a pivotal step" and "a cornerstone of the Company's long-term globalization strategy" supporting its planned entry into Amazon North America. This is a material operational and strategic milestone—a regulatory/industry qualification event that directly enables the company's international expansion into a major market. While not a discrete transaction (M&A), it is a significant business development that would affect a reasonable investor's assessment of the company's ability to execute its North American growth strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-07-01
The filing's primary disclosure under Item 5.07 reports the results of Allarity's June 26, 2026 annual stockholders meeting, including voting outcomes on seven proposals (director election, auditor ratification, equity plan amendment, executive compensation advisory vote, share issuance approval, certificate amendment, and meeting adjournment). While Item 8.01 also discloses a USPTO patent grant for the stenoparib DRP® companion diagnostic, the 8-K structure and content center on the shareholder vote results as the material event triggering the filing.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 75%
filed 2026-07-01
EX-99.1
The press release announces a change in the ADS ratio from 1 ADS per 60 ordinary shares to 1 ADS per 1,800 ordinary shares, effective July 6, 2026. This is economically equivalent to a one-for-thirty reverse ADS split (or one-for-fifty reverse split depending on calculation method). While technically a capital restructuring rather than a traditional dividend, ADS ratio changes and reverse splits are classified under dividend_distribution in the taxonomy as they represent a return/restructuring of capital to shareholders. The announcement is material as it affects the trading price, outstanding share count, and CUSIP number of the security.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-01
EX-99.1
This press release announces a product demonstration of Wetour's Conductor neural wristband, showcasing real-time 3D hand pose decoding and gesture-to-text conversion capabilities. The disclosure highlights a material operational and strategic milestone — the advancement of the company's core Physical AI platform (Orchestra) with demonstrated technical capabilities that position it for enterprise deployment. While not a discrete M&A, financial, or governance event, the announcement of a significant product capability advancement and the opening of an enterprise Early Access Program would affect a reasonable investor's assessment of the company's technology maturity and commercial readiness.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-01
EX-99.1
This press release announces a 1-for-25 reverse split effective July 6, 2026, following shareholder authorization at the November 2025 Annual General Meeting and Board approval on June 4, 2026. While reverse splits are governance/capital structure actions, they are material to investors as they affect share count, trading price, and market perception. The disclosure is clearly governance-related but does not fit the specific named categories (exec appointment/departure, compensation, shareholder vote results, or auditor change), making governance_other the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-01
EX-99.1
NewcelX announced successful completion of a Type B Pre-IND meeting with the FDA, receiving constructive feedback and regulatory alignment on its development strategy for NCEL-101 in combination with tegoprubart for type 1 diabetes. This is a material regulatory milestone that clears the path toward IND-enabling activities and clinical trial initiation, representing significant progress in the company's lead program development. While not a discrete transaction (M&A), financial event, or governance matter, this regulatory achievement is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-01
The 6-K discloses a reverse stock split (1-for-3) approved by the Board on May 4, 2026, effective July 6, 2026, reducing outstanding Class A Ordinary Shares from 10,259,764 to approximately 3,419,922. This is a governance and capital structure event that materially affects share count, trading mechanics, and convertible securities adjustments. While not a named governance type (exec appointment/departure, compensation, shareholder vote results), it is clearly a governance/corporate action matter that would affect a reasonable investor's assessment of share ownership and market mechanics.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-01
The Company's Board approved a reverse stock split (1-for-15) effective July 6, 2026, explicitly stated as intended to "regain compliance with the Nasdaq $1.00 minimum bid price requirement." This disclosure indicates the Company had fallen below the minimum bid price threshold and faces delisting risk absent the reverse split. The timing and stated purpose directly signal a continued listing compliance issue.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-01
Item 1.01
Forum Markets entered into Side Letter Amendment No. 2 on June 30, 2026, amending the Series B-3 Preferred Stock Purchase Agreement with Zippy, Inc. This amendment materially restructures the payment and measurement framework for the "Final Make Whole Amount" from a single true-up date to a trifurcated framework with three separate measurement and payment dates (July 31, September 30, and December 31, 2026), with corresponding sell periods and cash payment obligations. While technically an amendment to an existing agreement rather than a new transaction, the filing is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), and the restructuring of payment obligations and stock consideration mechanics constitutes a material modification to the underlying strategic partnership and capital structure arrangement. The amendment affects the timing, measurement, and risk allocation of a significant financial obligation tied to the Company's stock performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-01
Item 1.01
Quantum Drones Corporation, a wholly owned subsidiary of Quantum Cyber N.V., entered into definitive agreements on June 26, 2026 to acquire substantially all assets of Arcade Technology LLC's metal stamping business, including real property and manufacturing equipment in Bridgeport, Connecticut, for aggregate consideration of $3.2 million. This acquisition represents a strategic transition from technology licensing to vertically integrated domestic manufacturing with control of production infrastructure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-01
Item 5.07
Stockholders approved two material amendments to Arogo's Certificate of Incorporation at a special meeting: extension of the business combination deadline from June 29, 2026 to June 29, 2028 (98.1% approval), and elimination of the prohibition on stockholder action via written consent (98.1% approval). The filing also discloses significant redemption activity of 18,664 shares, leaving only 5,731 publicly held shares outstanding.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-07-01
The filing's primary substantive disclosure is the execution of an Amended Settlement Agreement on June 22, 2026, to resolve a securities class action (Crivellaro v. Singularity Future Technology Ltd.) for $5.8 million in aggregate cash. This is a material litigation settlement that would affect a reasonable investor's assessment of the company's financial obligations and legal exposure. While Item 5.07 reports shareholder vote results (including director re-elections, auditor ratification, and approval of a reverse stock split and authorized shares increase), the Item 1.01 disclosure of the settlement agreement is the most material event disclosed in this filing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-07-01
Item 1.01
Resideo announced a planned spin-off of its ADI Global Distribution business into an independent, publicly traded company, with a record date of July 20, 2026 and expected distribution date of August 3, 2026. To finance the transaction, ADI Escrow Issuer LLC completed a $400 million senior notes offering on June 30, 2026, and Resideo entered into a credit agreement on July 1, 2026 providing $600 million term facility and $500 million revolving facility.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-01
Banco de Chile placed senior dematerialized bearer bonds (Serie FG) in the local Chilean market on July 1, 2026, for CLF 400,000 with maturity November 1, 2030, at an average rate of 2.82%. This is a creation of a new direct financial obligation and was filed as Material Information with the Chilean Financial Market Commission, meeting the definition of debt_issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
The 6-K discloses the closing of a private placement of 15,841,585 Class A ordinary shares at $1.01 per share for approximately $16.0 million in gross proceeds. This is an unregistered equity issuance under Regulation S, which is a dilutive capital raise. The disclosure explicitly references the subscription agreement and closing date (June 29, 2026), making this a completed dilutive issuance material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This is a clear disclosure of shareholder vote results from Advanced Biomed Inc.'s annual meeting held on June 30, 2026. The filing reports final tabulation of votes on five proposals: election of five directors, say-on-pay advisory vote, frequency of say-on-pay votes, auditor ratification, and meeting adjournment. All proposals passed with strong majorities. This is a quintessential Item 5.07 disclosure and is material to investors as it documents the outcome of fundamental governance matters including board composition and auditor approval.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-01
The 6-K discloses the appointment of Mr. Gang Liu as Chief Financial Officer of Chanson International Holding, effective immediately on June 26, 2026. While the report also mentions Ms. Jihong Cai's resignation as CFO on the same date, the principal disclosed action is the appointment of a named executive to a C-suite officer role. The filing includes Mr. Liu's extensive 30+ years of accounting and financial management experience and references employment and indemnification agreements, consistent with a material executive appointment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 1.01
On July 1, 2026, Actelis Networks entered into an Exchange and Amendment Agreement with White Lion Capital LLC to issue 9,850,000 shares of common stock (comprising direct shares, pre-funded warrants, and common warrants) in exchange for White Lion's rights under the original Common Stock Purchase Agreement. This unregistered private placement, relying on Section 4(a)(2) and Regulation D exemptions, represents substantial dilution to existing shareholders and was triggered by the Company's Nasdaq delisting in April 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Cadrenal Therapeutics completed a private placement of 960,000 shares of common stock (or pre-funded warrants), Series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions, raising $3.0 million in gross proceeds at $3.1249 per unit, with up to $5.8 million in additional potential proceeds from warrant exercises. The unregistered securities extend the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised) and are subject to registration rights obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
The filing discloses the completion of a material business combination on June 25, 2026, whereby SPAC Merger Sub merged with TLGY and Company Merger Sub merged with SC Assets, resulting in TLGY and SC Assets becoming wholly-owned subsidiaries of StablecoinX. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets" and describes the consummation of the Business Combination, including the exchange of shares and conversion of warrants. This is a change of control transaction material to any investor.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-07-01
EX-99.1
The announcement discloses receipt of approximately COP 1 trillion (~COP 0.8 trillion to Ecopetrol proper) in payment from the National Government for an outstanding account receivable from the Fuel Price Stabilization Fund (FEPC) for Q2 2025, settled via issuance of short-term Treasury Securities. This is a material financial event—a significant cash inflow and resolution of a major receivable—but does not fit the specific event-type taxonomy (not earnings, debt issuance, dividend, or impairment). It is clearly financial in nature and material to investor assessment of liquidity and working capital.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-01
The 6-K furnishes a "Consolidated Synthetic remote voting map" disclosing the results of an Extraordinary General Meeting held on July 2, 2026. The document presents voting tallies on seven items including board size, director nominations (Márcio de Andrade Schettini and Oscar Rodríguez Herrero), and fiscal council establishment, with vote counts broken down by share class and approval/rejection/abstention. This is a direct disclosure of shareholder vote results as required under Item 5.07 equivalent for foreign private issuers.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
Inogen appointed Andrew Reding as Executive Vice President and Chief Operating Officer, a newly created C-suite role effective July 6, 2026. The appointment includes compensatory arrangements comprising a base salary of $500,000, a 70% bonus target, a $100,000 sign-on bonus, and 130,000 RSUs vesting over three years, approved under Nasdaq Listing Rule 5635(c)(4).
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-07-01
Safe Bulkers declared quarterly cash dividends of $0.50 per share on its Series C and Series D Cumulative Redeemable Perpetual Preferred Shares, payable July 30, 2026. This is a routine but material dividend declaration on preferred equity securities, clearly falling within the dividend_distribution category.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-01
Item 8.01
The filing discloses a declaration of quarterly cash distributions on three series of preferred shares (Series A, B, and C) with specific per-share amounts ($0.453125, $0.4921875, and $0.4921875 respectively), a record date of July 15, 2026, and a payment date of July 30, 2026. This is a routine but material dividend declaration that would affect preferred shareholders' assessment of the company's capital allocation and cash generation capacity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
Stephanie C. Bush was elected to the Board of Directors of Employers Holdings, Inc. on June 25, 2026, with her term commencing July 1, 2026, increasing board size to nine members. Her appointment reflects her extensive insurance leadership background and expertise in underwriting, product, and distribution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Neurogene entered into an underwriting agreement to issue 3.5 million shares of common stock at $30.00 per share, plus 666,666 pre-funded warrants, with underwriters exercising a full 30-day option for an additional 624,999 shares, expected to raise approximately $134.8 million in net proceeds.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-07-01
Item 4.01
This is a clear auditor change disclosure under Item 4.01. The Audit Committee dismissed CBIZ CPAs as the independent registered public accounting firm on June 25, 2026, and appointed Ernst & Young LLP as the successor auditor. The filing explicitly documents the dismissal, the absence of disagreements or adverse audit opinions, and the one reportable event (material weakness in internal controls over financial reporting). This is a material governance event affecting investor confidence in financial reporting oversight.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-01
Item 8.01
Missouri American Water filed a rate request with the MoPSC seeking approximately $179 million in annualized incremental revenue to support $1.6 billion in capital investments over a three-year period. This is a material operational and regulatory event—the filing of a major rate case is a significant business development for a regulated utility that directly affects future revenue and profitability. While not a specific named event type, it is clearly operational/regulatory in nature and material to investors assessing the company's growth and earnings trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-01
Item 8.01
iBio disclosed preclinical data from a non-human primate study of IBIO-610, a lead candidate antibody, demonstrating 98% inhibition of active Activin E through eight weeks and improved body composition when combined with semaglutide, representing a material clinical milestone supporting advancement toward human trials.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-01
Item 8.01
The filing discloses confirmation of cash dividends payable to common and preferred shareholders: $0.24 per share for July 2026 common stock (payable July 30, 2026) and $0.14583 per share monthly for Q3 2026 Series C Preferred Stock. This is a routine but material dividend declaration typical of REITs, which are required to distribute substantially all ordinary taxable income to maintain tax status. The disclosure includes record dates, payment dates, and amounts for both security classes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-01
Item 5.02
The filing discloses the election of two new directors (Diya Jolly and Michael Yang) to the Board effective June 29, 2026, along with significant governance changes including the appointment of Shane Trigg as Chairman and Winifred Webb as Lead Independent Director. While the section also includes the retirement of two long-serving directors (Andreas von Blottnitz and Janet Kerr), the primary focus and substantive action centers on the appointment of new directors and restructuring of board leadership roles, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-01
Item 7.01
The filing discloses termination of a Formal Agreement with the OCC dated January 14, 2025, effective June 30, 2026. The OCC stated that "the safety and soundness of the Bank and its compliance with the laws and regulations does not require the continued existence of the [Formal] Agreement." This represents a material regulatory milestone—resolution of a formal enforcement action—that affects the company's regulatory status, cost structure, and strategic flexibility. While this is fundamentally a regulatory/governance event rather than a specific named category (not a restatement, auditor change, or going-concern issue), it is clearly material to investors as it signals improved regulatory standing and expected cost reductions of over $5 million annually.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-07-01
Item 2.03
Gray Media issued $70 million aggregate principal amount of 7.250% Senior Secured First Lien Notes due 2033 in a private placement on June 30, 2026, ranking equally with existing $775 million of notes in the same series. The notes were issued to accredited investors and represent a material increase in the company's outstanding debt obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-07-01
Item 8.01
Gray Media acquired six television stations from American Spirit Media for $50 million, with the first closing completed on July 1, 2026 ($40 million paid) and the second closing anticipated in Q4 2026. The acquisition is funded by the concurrent debt issuance and is expected to be cash flow accretive as part of Gray's strategy to pursue prudent tuck-in acquisitions.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The Compensation Committee approved retention bonuses for named executives Eric Schlorff and Kevin Chung with vesting schedules and equity components under the 2022 Omnibus Incentive Plan. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from a departure or appointment. The retention structure and equity grants are material to investor assessment of executive incentives and capital allocation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
Item 2.01
Radnostix completed the acquisition of the Lara System technology platform and Ellexa Explorer Software from Lucerno Dynamics on June 25, 2026, for $900,000 in initial consideration plus contingent milestone payments. The transaction was structured with related financing arrangements including a convertible note and note amendments.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-01
Item 2.03
In connection with the asset acquisition, Radnostix entered into a Note Agreement and amended existing notes, creating new or modified direct financial obligations as part of the transaction financing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
Item 3.02
Radnostix issued unregistered equity securities to the sellers, including stock closing consideration, regulatory milestone payment shares, and sales milestone payment shares, in a transaction exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses the election of George M. Ristau, Jr. to the Board of Directors on July 1, 2026, filling a vacancy created by the passing of James A. Lentz, and his concurrent appointment to the Audit Committee. While the section mentions the departure context (death of Lentz), the principal disclosed action is the appointment of a new director and committee member, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-01
Item 2.02
This is a clear earnings release disclosing Bassett Furniture's second quarter financial results for the fiscal year ending November 28, 2026. The Item 2.02 filing includes a news release (Exhibit 99.1) announcing Q2 results with detailed financial statements, segment information, and management commentary. The disclosure covers revenues ($83.8M), operating income ($2.2M), gross margin (56.5%), diluted EPS ($0.24), and cash flow metrics, making it a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-01
Item 2.01
NHC completed the acquisition of 35 healthcare facilities (32 skilled nursing facilities and 3 independent living facilities) from National Health Investors, Inc. for $560 million on July 1, 2026. The transaction converts NHC's prior leasing arrangement into ownership and is expected to be accretive to earnings and cash flow.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-01
Item 2.03
NHC drew down $475 million under a senior unsecured term loan facility and $55 million under a senior unsecured revolving credit facility (totaling $530 million) on the closing date to finance the $560 million acquisition.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-01
Item 8.01
The filing discloses the declaration and payment of the Trust's first cash distribution of $457,924.72 to shareholders of record on July 2, 2026, paid on July 8, 2026, representing premiums received from option-writing activities. The disclosure also outlines the Trust's intention to make ongoing monthly distributions from premium income. This is a classic dividend_distribution event, material to investors as it communicates the Trust's income-generation capability and distribution policy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This Item 5.07 disclosure reports the complete voting results from Laird Superfood's June 25, 2026 Annual Meeting of Stockholders, including election of eight directors, ratification of KPMG LLP as auditor, advisory votes on executive compensation and compensation frequency, and approval of an amendment to the 2020 Stock Incentive Plan. All proposals received sufficient votes for approval, and the Board determined to hold future advisory compensation votes annually based on the plurality result for Proposal 4.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-01
Item 1.01
CareView entered into a Fifteenth Amendment to its Credit Agreement with PDL Investment Holdings, LLC, extending the Maturity Date to September 30, 2026. This material modification of the company's direct financial obligation extends the debt maturity and likely involves renegotiated terms, reflecting ongoing refinancing pressure.
View raw filing on EDGAR →